Antibacterial and Antibiofilm Activities of Diclofenac Against Levofloxacin-resistant Isolates; Emphasizing Repurposing of Diclofenac

Overview

Journal Iran J Microbiol

Publisher Tehran University of Medical Sciences

Specialty Infectious Diseases

Date 2024 Jun 10

PMID 38854979

Authors

Ingy El-Soudany

Ibrahim A Abdelwahab

Marwa Atef Yakout

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: is an opportunistic pathogen causing nosocomial infections. Diclofenac is an anti-inflammatory drug that is considered a non-antibiotic drug. This study assessed the antibacterial and antibiofilm effects of diclofenac and levofloxacin/diclofenac combination against levofloxacin resistant isolates.

Materials And Methods: Minimum inhibitory concentration was determined using broth microdilution method for levofloxacin, diclofenac, and levofloxacin/diclofenac combination. Biofilm forming capacity and biofilm inhibition assay were determined. Relative gene expression was measured for efflux pump genes; , and genes and biofilm related genes , and without and with diclofenac and the combination.

Results: Diclofenac demonstrated MIC of 1 mg/ml. The combination-with ½ MIC diclofenac-showed synergism where levofloxacin MIC undergone 16-32 fold decrease. All the isolates that overexpressed and showed a significant decrease in gene expression in presence of diclofenac or the combination. The mean percentage inhibition of biofilm formation with diclofenac and the combination was 40.59% and 46.49%, respectively. This agreed with biofilm related genes expression investigations.

Conclusion: Diclofenac showed an antibacterial effect against The combination showed synergism, significant reduction in biofilm formation and in the relative level of gene expression. Furthermore, it can potentiate the levofloxacin activity or revert its resistance.

References

Thenmozhi R, Nithyanand P, Rathna J, Pandian S . Antibiofilm activity of coral-associated bacteria against different clinical M serotypes of Streptococcus pyogenes. FEMS Immunol Med Microbiol. 2009; 57(3):284-94. DOI: 10.1111/j.1574-695X.2009.00613.x. View

Chang L, Chen H, Chang C, Lee T, Wu W . Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 2004; 53(3):518-21. DOI: 10.1093/jac/dkh094. View

Reslinski A, Dabrowiecki S, Glowacka K . The impact of diclofenac and ibuprofen on biofilm formation on the surface of polypropylene mesh. Hernia. 2013; 19(2):179-85. PMC: 4372680. DOI: 10.1007/s10029-013-1200-x. View

Sanchez M, Luis Martinez J . Overexpression of the Efflux Pumps SmeVWX and SmeDEF Is a Major Cause of Resistance to Co-trimoxazole in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2018; 62(6). PMC: 5971588. DOI: 10.1128/AAC.00301-18. View

Zhang L, Li X, Poole K . SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2001; 45(12):3497-503. PMC: 90859. DOI: 10.1128/AAC.45.12.3497-3503.2001. View

Seukep J, Sandjo L, Ngadjui B, Kuete V . Antibacterial and antibiotic-resistance modifying activity of the extracts and compounds from Nauclea pobeguinii against Gram-negative multi-drug resistant phenotypes. BMC Complement Altern Med. 2016; 16:193. PMC: 4937598. DOI: 10.1186/s12906-016-1173-2. View

Azimi A, Aslanimehr M, Yaseri M, Shadkam M, Douraghi M . Distribution of smf-1, rmlA, spgM and rpfF genes among Stenotrophomonas maltophilia isolates in relation to biofilm-forming capacity. J Glob Antimicrob Resist. 2020; 23:321-326. DOI: 10.1016/j.jgar.2020.10.011. View

Mohammed M, Ahmed M, Anwer B, Aboshanab K, Aboulwafa M . Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones. PLoS One. 2020; 15(8):e0238195. PMC: 7449414. DOI: 10.1371/journal.pone.0238195. View

Oliveira I, Borges A, Borges F, Simoes M . Repurposing ibuprofen to control Staphylococcus aureus biofilms. Eur J Med Chem. 2019; 166:197-205. DOI: 10.1016/j.ejmech.2019.01.046. View

10.

Gibb J, Wong D . Antimicrobial Treatment Strategies for : A Focus on Novel Therapies. Antibiotics (Basel). 2021; 10(10). PMC: 8532924. DOI: 10.3390/antibiotics10101226. View

11.

Leao C, Borges A, Simoes M . NSAIDs as a Drug Repurposing Strategy for Biofilm Control. Antibiotics (Basel). 2020; 9(9). PMC: 7558876. DOI: 10.3390/antibiotics9090591. View

12.

Elbaradei A, Yakout M . Stenotrophomonas maltophilia: Genotypic Characterization of Virulence Genes and The Effect of Ascorbic Acid on Biofilm Formation. Curr Microbiol. 2022; 79(6):180. PMC: 9068641. DOI: 10.1007/s00284-022-02869-7. View

13.

Riordan J, Dupre J, Cantore-Matyi S, Kumar-Singh A, Song Y, Zaman S . Alterations in the transcriptome and antibiotic susceptibility of Staphylococcus aureus grown in the presence of diclofenac. Ann Clin Microbiol Antimicrob. 2011; 10:30. PMC: 3158543. DOI: 10.1186/1476-0711-10-30. View

14.

Masubuchi Y, Ose A, Horie T . Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab Dispos. 2002; 30(10):1143-8. DOI: 10.1124/dmd.30.10.1143. View

15.

Junco S, Bowman M, Turner R . Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. Int J Antimicrob Agents. 2021; 58(2):106367. DOI: 10.1016/j.ijantimicag.2021.106367. View

16.

Cho H, Sung J, Kwon K, Koo S . Expression of Sme efflux pumps and multilocus sequence typing in clinical isolates of Stenotrophomonas maltophilia. Ann Lab Med. 2012; 32(1):38-43. PMC: 3255492. DOI: 10.3343/alm.2012.32.1.38. View

17.

Ebrahim-Saraie H, Heidari H, Soltani B, Mardaneh J, Motamedifar M . Prevalence of antibiotic resistance and integrons, and genes in clinical isolates of from a tertiary care hospital in Southwest Iran. Iran J Basic Med Sci. 2019; 22(8):872-877. PMC: 6760486. DOI: 10.22038/ijbms.2019.31291.7540. View

18.

Boyd N, Teng C, Frei C . Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. Front Cell Infect Microbiol. 2021; 11:684515. PMC: 8165386. DOI: 10.3389/fcimb.2021.684515. View

19.

Brooke J . New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther. 2013; 12(1):1-4. DOI: 10.1586/14787210.2014.864553. View

20.

Pereira S, Domingues V, Theriaga J, de Jesus Chasqueira M, Paixao P . Non-Antimicrobial Drugs: Etodolac as a Possible Antimicrobial or Adjuvant Agent Against ESKAPE Pathogens. Open Microbiol J. 2018; 12:288-296. PMC: 6142654. DOI: 10.2174/1874285801812010288. View